Filip Dubovsky - Nov 5, 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President, R&D
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Nov 5, 2023
Transactions value $
$5,104
Form type
4
Date filed
11/7/2023, 05:30 PM
Previous filing
Sep 19, 2023
Next filing
Dec 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise $9.88K +1.4K +2.71% $7.06 53K Nov 5, 2023 Direct F1
transaction NVAX Common Stock Tax liability -$4.78K -677 -1.28% $7.06 52.3K Nov 5, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -1.4K -100% $0.00* 0 Nov 5, 2023 Common Stock 1.4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
F2 Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F3 The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the November 5, 2020 grant date, in each case subject to continued employment with the Company through such vesting date.